HC Wainwright Estimates Alumis’ Q1 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright lifted their Q1 2025 earnings estimates for shares of Alumis in a research note issued to investors on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($1.07) per share for the quarter, up from their previous estimate of ($1.29). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.39) EPS.

A number of other equities research analysts also recently commented on ALMS. Oppenheimer started coverage on shares of Alumis in a research report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Alumis currently has a consensus rating of “Buy” and a consensus target price of $26.00.

Alumis Stock Up 20.0 %

Shares of NASDAQ:ALMS opened at $5.64 on Friday. Alumis has a fifty-two week low of $3.18 and a fifty-two week high of $13.53. The firm’s 50-day simple moving average is $5.39 and its 200-day simple moving average is $8.34.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC acquired a new stake in shares of Alumis in the 3rd quarter worth approximately $3,266,000. State Street Corp purchased a new stake in Alumis during the third quarter worth $866,000. Charles Schwab Investment Management Inc. acquired a new stake in Alumis in the third quarter valued at $1,160,000. Stifel Financial Corp purchased a new position in shares of Alumis in the third quarter valued at $931,000. Finally, Barclays PLC acquired a new position in shares of Alumis during the 3rd quarter worth $197,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.